Glumetinib
Gastroesophageal Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
45 Active assets in the Gastroesophageal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fluorouracilum Incyte Corporation | Phase 1/2 | B |
Carboplatin Iambic Therapeutics, Inc | Phase 1/2 | B |
Xaliplatin Incyte Corporation | Phase 1/2 | B |
Cyclophosphamide Diwakar Davar | Phase 2 | B |
Pembrolizumab Diwakar Davar | Phase 2 | B |
View all 50 →
Same molecule, other indications
Glumetinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →